6Martyn F. Biddiscombe, Omar S. Usmani, Peter J. Barnes. A system for the production and delivery of monodisperse salbutamol aerodold to the lungs[J].Int J. Pharm,2003,254 : 243- 253.
8Zeng MX, Martin GP, Marriott C, et al. Lactose as a carrier in dry powder formulations: the influence of surface characteristics on drug delivery[J]. J Pharm Sci. 2001,90 ( 9 ) :1424-- 1434.
9Larhrib H, Zeng XM, Martin GP, et al. The use of different grades os lactose as a carrier for aerosolized salbutamol sulphate[J]. Int J Pharm, 1999, 191 ( 1 ) : 1 - 14.
10Okmnoto H, Aoki M, Danjo K. A novel apparatus for rat in vivo evaluation of dry powder formulations for pulmonary administration[J]. J Pharm Sci, 2(100,89(8): 1028-1035.
二级参考文献61
1[2]广西壮族自治区卫生厅.广西中药材标准.南宁:广西科学技术出版社,1990.54.
2[1]Saudek CD.Novel forms of insulin delivery[J].Endocrinol Metab Clin North Am,1997,26(3):599-610.
3[2]Heubner W,de Jongh SE,Laquer E.Uber inhalation von insulin[J].Klin Wochensch,1924,51:2342-2343.
4[3]Gale EA.Two cheers for inhaled insulin[J].Lancet,2001,357(9253):324-325.
5[4]Wigley FW,Londono JH,Wood SH,et al.Insulin across respiratory mucosa byaerosol delivery[J].Diabetes,1971,20:552-556.
6[5]Elliott RB,Edgar BW,Pilcher CC,et al.Parenteral absorption of insulin from thelung in diabetic children[J].Aust Paediatr J,1987,23(5):293-297.
7[6]Laube BL,Georgopoulos A,Adams GK.Preliminary study of the efficacy ofinsulin aerosol delivered by oral inhalation in diabetic patients[J].JAMA,1993,269(16):2106-2109.
8[7]Heinemann L,Traut T,Heise T.Time-action profile of inhaled insulin[J].DiabeticMedicine,1997,14(1):63-72.
9[8]Laube BL,Benedict GW,Dobs AS.The lung as an alternative route of delivery forinsulin in controlling postpradial glucose levels in patients with diabetes[J].Chest,1998,114(7):1734-1739.
10[9]Gelfand RA,Schwartz SL,Horton M,et al.Pharmacological reproducilibility ofinhaled human insulin pre-meal dosing in patients with type 2 diabetes mellitus(NIDDM)[J].Diabetes,1998,47(suppl 1):A99.
